In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: April 2009

Executive Summary

Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries includes these highlights from February 2009: Pharmaceutical alliance money was weak: the biggest deal of the month was Novartis' $150mm license to Portola's Phase II cardio candidate elinogrel. In M&A, Lundbeck was on top with its takeover of spec pharma Ovation, expanding the European company's neurology drug portfolio in the US. Meanwhile, Beckman Coulter improved its position in the chemistry testing market by buying Olympus' diagnostic systems unit. And Medtronic made two major cardiovascular acquisitions: Ventor and CoreValve. Finally, pharmaceutical financing tripled three times since January to $1.6bn thanks to more than $1bn in public offerings including $684mm netted by BMS, which sold 15% of Mead Johnson through an IPO--the first in the Rx space in one year--as well as Vertex's $314mm FOPO.
Advertisement
Advertisement
UsernamePublicRestriction

Register

IV003285

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel